CYP2B6 and neoplasm: According to the model with CYP2B6 SNVs or haplotypes, the primary tumour response was better in patients under 1.5 years than in older children, and girls were found to expect more favourable therapeutic outcomes than boys in both models (P = 0.03) (Table 6).